49855-91-6

Usage

Uses

Since the specific properties, uses, or roles of (2S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-[[(phenylmethoxy)carbonyl]amino]butanoic acid are not explicitly provided in the materials, its applications would require further research or information. However, based on its classification as an amino acid and the presence of various functional groups, it is possible that it could be used in the following ways:
Used in Pharmaceutical Industry:
(2S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-[[(phenylmethoxy)carbonyl]amino]butanoic acid could be used as a pharmaceutical compound for its potential involvement in biochemical reactions, which may have therapeutic applications.
Used in Biochemical Research:
(2S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-[[(phenylmethoxy)carbonyl]amino]butanoic acid could serve as a research tool in studying the mechanisms of amino acid interactions and their roles in biological processes.
Used in Drug Development:
The unique structure of (2S)-4-[[(1,1-Dimethylethoxy)carbonyl]amino]-2-[[(phenylmethoxy)carbonyl]amino]butanoic acid may offer opportunities for the development of new drugs, particularly if its properties can be harnessed to target specific biological pathways or receptors.

InChI:InChI=1S/C17H24N2O6/c1-17(2,3)25-15(22)18-10-9-13(14(20)21)19-16(23)24-11-12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3,(H,18,22)(H,19,23)(H,20,21)/t13-/m0/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 10270-94-7 4--L-2,4-diaminobutyric acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 182618-33-3 (S)-4-Amino-2-benzyloxycarbonylamino-butyric acid methyl ester 
• 13907-82-9 N²-benzyloxycarbonyl-L-glutamine methyl ester 
• 62234-40-6 (2S)-2-{[(benzyloxy)carbonyl]amino}-4-(dimethylamino)butanoic acid 
• 3350-14-9 (S)-2-Benzyloxycarbonylamino-4-tert-butoxycarbonylamino-butyric acid methyl ester 

Downstream Products

• 177723-14-7 (S)-2-((S)-2-Benzyloxycarbonylamino-4-tert-butoxycarbonylamino-butyrylamino)-3-phenyl-propionic acid methyl ester 
• 151132-82-0 Nα-Z-Nγ-Fmoc-L-2,4-diaminobutyric acid 
• 125156-36-7 2--4--L-2,4-diaminobutyric p-nitrophenyl ester 
• 1026636-40-7 [(2-benzyloxycarbonylamino-4-tert-butoxycarbonylamino-butyryl)-(2,2-dimethoxy-ethyl)-amino]-acetic acid tert-butyl ester 
• 583048-21-9 methyl N-{(2S)-2-{[(benzyloxy)carbonyl]amino}-4-[(tert-butoxycarbonyl)amino]butanoyl}-L-threoninate 
• 753501-07-4 (3-benzyloxycarbonylamino-4-oxo-4-piperidin-1-yl-butyl)-carbamic acid tert-butyl ester 
• 130900-01-5 Nα-carbobenzoxy-Nγ-tert-butoxycarbonyl-2,4-diaminobutyryl benzyl ester 
• 929087-74-1 Nα-carbobenzoxy-Nγ-tert-butoxycarbonyl-2,4-diaminobutyrylglycine methyl ester 
• 118507-51-0 ((S)-4-Amino-2-benzyloxycarbonylamino-butyrylamino)-acetic acid methyl ester 
• 124921-76-2 (2S)-4-Amino-2-(benzyloxycarbonylamino)butansaeure-benzylester 
• 184576-25-8 tert-butyl 2-[(3S)-4-(2-[(benzyloxycarbonyl)amino]acetyl)-3-[[(tert-butoxycarbonyl)amino]ethyl]-2-oxopiperazinyl]acetate 
• 244185-30-6 tert-butyl N-[(3S)-3-amino-3-carbamoyl propyl]carbamate 
• 244185-29-3 2--4--L-2,4-diaminobutyric amide 

Relevant academic research and scientific papers

BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS

Compounds of general formula (I) wherein R1, R2, R3, R4, R5 and X are as defined herein are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respirator

Macrocyclic hexaoxazoles: Influence of aminoalkyl substituents on RNA and DNA G-quadruplex stabilization and cytotoxicity

A series of 24-membered macrocyclic hexaoxazoles containing one or two aminoalkyl substituents was synthesized and evaluated for cytotoxicity and for their ability to selectively stabilize G-quadruplex DNA and RNA. The most cytotoxic analog 4a, with IC50 values of 25 and 130 nM using KB3-1 and RPMI 8402 cells, is efficacious in vivo in athymic nude mice with a human tumor xenograft from the breast cancer cell line MDA-MB-435.

THERAPEUTIC COMPOUNDS

The invention provides compounds of formula (I) wherein A, B, R1, F, G, n, n' and the dotted line have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.

Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors

A series of novel transglutaminase inhibitors was prepared, based on the scaffold of a commonly used peptide substrate and bearing an electrophilic maleimide group. These compounds were evaluated in vitro and shown to lead to irreversible inactivation of tissue transglutaminase. Comparison with inhibitors studied previously provides insight into the steric environment of the enzyme active site.

N(ω)-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase

Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-

Modification of receptor selectivity and functional activity of cyclic cholecystokinin analogues

We reported earlier on the synthesis and biological activity at the CCK-B receptor of cyclized derivatives of CCK. These peptides, in which the positions 28 and 31 were replaced by lysine residues, were bridged by a succinyl moiety. To determine the importance of the nature and size of the cyclic structure, cyclic analogues were synthesized in which: (i) the lysine residues were replaced by ornithine and diaminobutyric acid and (ii) the succinic moiety was replaced by a malonic, adipic and glutaric moiety. They were tested For their ability to inhibit the specific binding of 125I-BH-CCK-8 to CCK receptors in rat pancreatic acini and guinea pig brain membranes. They were also evaluated for their ability to stimulate amylase secretion from rat pancreatic acini. The potency and selectivity of these analogues were compared with those obtained with CCK-4 and compound JIMV320, a potent and selective CCK-B receptor ligand synthesized earlier in our laboratory.